SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study

Published on 10 Jan 2025 on Zacks · via Yahoo Finance

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage...

Read the rest of the article

Start tracking your investments with Statfolio

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from...

TipRanks · via Yahoo Finance 11 Jan 2025

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stag...

Zacks · via Yahoo Finance 10 Jan 2025

On Thursday, Sanofi SA (NASDAQ:SNY) released results from the IRAKLIA phase 3 study evaluating th...

Benzinga · via Yahoo Finance 9 Jan 2025

Vaccine stocks and EV maker Lucid Technologies (LCID) are among today’s biggest winners today. Va...

Insider Monkey · via Yahoo Finance 7 Jan 2025

DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis ...

Zacks · via Yahoo Finance 7 Jan 2025

SNY's reasonable valuation, improving top-line performance, contributions from new product launch...

Zacks · via Yahoo Finance 7 Jan 2025

AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales...

Zacks · via Yahoo Finance 6 Jan 2025

Duquesne Family Office's chief is cashing in his chips on two leading artificial intelligence (AI...

The Motley Fool · via AOL 24 Dec 2024

(You can read the full research report on United-Guardian here >>>) Why Haven't You Looked at Zac...

Zacks · via Yahoo Finance 24 Dec 2024

Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to...

Zacks · via Yahoo Finance 23 Dec 2024